Analysis reveals cfDNA dynamics and tumor burden tracking in glioblastoma during temozolomide treatment, indicating its potential as a liquid biopsy tool.
Key Points
Cell-free DNA serves as a promising biomarker to monitor glioblastoma progression and treatment response.
Increased cfDNA yield during temozolomide treatment points to its relevance in assessing therapy efficacy.
The co-culture system effectively differentiates contributions of glioblastoma and normal astrocyte cells to cfDNA.
Findings highlight the practical application of cfDNA in managing glioblastoma with non-invasive monitoring techniques.